# US 2018/0021332 A1 · Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021332 A1
- Document ID: US20180021332A1
- Status: Published application
- Kind: A1
- Application number: 15/549,881
- Filed: 2016-02-09
- Published: 2018-01-25
- Earliest claimed: 2015-02-10
- Assignees: Astex Therapeutics Limited
- Applicants: Astex Therapeutics Limited
- Inventors: Diego Fernando Domenico BROGGINI
- Web page: https://patentgrep.com/patent/US20180021332A1

## CPC

- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/4858: {Organic compounds}
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C09K 15/20: containing nitrogen and oxygen
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C09K: MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE

## Abstract

The invention relates to pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine, or a pharmaceutically acceptable salt thereof or a solvate thereof; to processes for the preparation of said compositions and to the use of said compositions for the manufacture of a medicament for the prophylaxis of or the treatment, in particular the treatment, of diseases, e.g. cancer

## Claims

### Claim 1

A method of increasing the chemical stability of a pharmaceutical composition comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine, a pharmaceutically acceptable salt thereof or a solvate thereof, said method comprising providing a composition comprising a formaldehyde scavenger and N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim at position 2

2-5. (canceled)

### Claim 6

A method of preventing, postponing, slowing down or diminishing the transformation of N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine, a pharmaceutically acceptable salt thereof or a solvate thereof, contained in a pharmaceutical composition, into 6,8-dimethoxy-4-(1-methylethyl)-1-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine, a pharmaceutically acceptable salt thereof or a solvate thereof, comprising adding a formaldehyde scavenger to said composition.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the formaldehyde scavenger is meglumine.

### Claim 8 (depends on 6)

The method according to claim 6, wherein the pharmaceutical composition is a tablet or a capsule.

### Claim 9 (depends on 6)

The method according to claim 6, wherein the composition comprises N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine base.

### Claim 10

A pharmaceutical composition comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine, a pharmaceutically acceptable salt thereof or a solvate thereof; a formaldehyde scavenger; and a pharmaceutically acceptable carrier.

### Claim 11 (depends on 10)

A pharmaceutical composition according to claim 10 comprising from about 0.1 to about 3% w/w of the formaldehyde scavenger.

### Claim 12 (depends on 10)

A pharmaceutical composition according to claim 10, wherein the composition is a tablet or a capsule.

### Claim 13 (depends on 10)

A pharmaceutical composition according to claim 10, wherein the composition comprises from 0-2% w/w of 6,8-dimethoxy-4-(1-methylethyl)-1-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 14 (depends on 13)

A pharmaceutical composition according to claim 13, wherein the composition comprises from 0-0.05% w/w of 6,8-dimethoxy-4-(1-methylethyl)-1-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 15 (depends on 10)

A pharmaceutical composition according to claim 10 comprising from 2 mg to 6 mg base equivalent of N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine, a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 16 (depends on 10)

A pharmaceutical composition according to claim 10, wherein the formaldehyde scavenger is meglumine.

### Claim 17 (depends on 10)

A pharmaceutical composition according to claim 10, wherein the composition comprises N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine base.

### Claim 18 (depends on 10)

A method of treating cancer in a patient, comprising administering to the patient a pharmaceutical composition according to claim 10 daily for 3 weeks (3 weeks on), followed by 1 week wherein the composition is not administered (1 week off), and repeating this cycle of 3 weeks on, 1 week off.

### Claim 19

(canceled)

### Claim 20 (depends on 10)

A method of treating cancer in a patient, comprising administering to the patient a pharmaceutical composition according to claim 10 daily for 1 week (1 week on), followed by 1 week wherein the composition is not administered (1 week off), and repeating this cycle of 1 week on, 1 week off.

### Claim 21

(canceled)

### Claim 22 (depends on 10)

A method of treating cancer in a patient, comprising administering to the patient a pharmaceutical composition according to claim 10 daily.

### Claim 23 (depends on 10)

A method of treating cancer in a patient, comprising administering to the patient a pharmaceutical composition according to claim 10 once daily.

### Claim 24 (depends on 22)

A method of treating cancer in a patient according to claim 22 wherein the daily dose ranges from 6 mg to 9 mg base equivalent.

### Claim 25 (depends on 22)

A method of treating cancer in a patient according to claim 22 wherein the daily dose is 6 mg base equivalent.

### Claim 26 (depends on 22)

A method of treating cancer in a patient according to claim 22 wherein the daily dose is 8 mg base equivalent.

### Claim 27 (depends on 22)

A method of treating cancer in a patient according to claim 22 wherein the daily dose is 9 mg base equivalent.

### Claim 28 (depends on 22)

A method according to claim 22 wherein the cancer is bladder cancer, urothelial cancer, metastatic urothelial cancer, surgically unresectable urothelial cancer, cholangiocarcinoma, or non-muscle-invasive bladder cancer.

### Claim 29 (depends on 22)

A method according to claim 22 wherein the cancer is bladder cancer.

### Claim 30 (depends on 22)

A method according to claim 22 wherein the cancer is urothelial cancer.

### Claim 31 (depends on 22)

A method according to claim 22 wherein the cancer is metastatic urothelial cancer.

### Claim 32 (depends on 22)

A method according to claim 22 wherein the cancer is surgically unresectable urothelial cancer.

### Claim 33 (depends on 22)

A method according to claim 22 wherein the cancer is cholangiocarcinoma.

### Claim 34 (depends on 22)

A method according to claim 22 wherein the cancer is non-muscle-invasive bladder cancer.

### Claim 35 (depends on 28)

A method according to claim 28 wherein the cancer is a cancer with FGFR genomic alterations.

### Claim 36 (depends on 35)

A method according to claim 35 wherein the FGFR genomic alterations are translocations, fusions and/or mutations.

### Claim 37 (depends on 36)

A method according to claim 36 wherein the alteration is a FGFR3-TACC3 translocation.

### Claim 38 (depends on 36)

A method according to claim 36 wherein the alteration is a mutation.

### Claim 39 (depends on 38)

A method according to claim 38 wherein the mutation is R248C.

### Claim 40 (depends on 38)

A method according to claim 38 wherein the mutation is S249C.

### Claim 41 (depends on 22)

A method according to claim 22 wherein the cancer is advanced or refractory non small cell lung cancer (NSCLC), breast cancer, glioblastoma multiforme, urothelial cancer, ovarian cancer, head and neck cancer, oesophageal cancer, gastric cancer or cholangiocarcinoma.

### Claim 42 (depends on 22)

A method according to claim 22 wherein the cancer is multiple myeloma, myeloproliferative disorders, endometrial cancer, prostate cancer, bladder cancer, lung cancer, ovarian cancer, breast cancer, gastric cancer, colorectal cancer, or oral squamous cell carcinoma.

### Claim 43 (depends on 22)

A method according to claim 22 wherein the cancer is endometrial, ovarian, gastric, hepatocellular, uterine, cervix or colorectal cancer.

### Claim 44 (depends on 22)

A method according to claim 22 wherein the cancer is advanced or refractory non small cell lung cancer (NSCLC), breast cancer, glioblastoma multiforme, urothelial cancer, ovarian cancer, head and neck cancer, oesophageal cancer, gastric cancer, cholangiocarcinoma, multiple myeloma, myeloproliferative disorders, endometrial cancer, prostate cancer, bladder cancer, lung cancer, colorectal cancer, oral squamous cell carcinoma, hepatocellular cancer, uterine cancer, or cervix cancer, and wherein the cancer is a cancer with FGFR genomic alterations.

### Claim 45 (depends on 44)

A method according to claim 44 wherein the FGFR genomic alterations are translocations, fusions and/or mutations.
